Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America.
PLoS One. 2013;8(3):e56044. doi: 10.1371/journal.pone.0056044. Epub 2013 Mar 7.
Cost effectiveness analyses (CEA) can provide useful information on how to invest limited funds, however they are less useful if different analysis of the same intervention provide unclear or contradictory results. The objective of our study was to conduct a systematic review of methodologic aspects of CEA that evaluate Interferon Gamma Release Assays (IGRA) for the detection of Latent Tuberculosis Infection (LTBI), in order to understand how differences affect study results.
A systematic review of studies was conducted with particular focus on study quality and the variability in inputs used in models used to assess cost-effectiveness. A common decision analysis model of the IGRA versus Tuberculin Skin Test (TST) screening strategy was developed and used to quantify the impact on predicted results of observed differences of model inputs taken from the studies identified.
Thirteen studies were ultimately included in the review. Several specific methodologic issues were identified across studies, including how study inputs were selected, inconsistencies in the costing approach, the utility of the QALY (Quality Adjusted Life Year) as the effectiveness outcome, and how authors choose to present and interpret study results. When the IGRA versus TST test strategies were compared using our common decision analysis model predicted effectiveness largely overlapped.
Many methodologic issues that contribute to inconsistent results and reduced study quality were identified in studies that assessed the cost-effectiveness of the IGRA test. More specific and relevant guidelines are needed in order to help authors standardize modelling approaches, inputs, assumptions and how results are presented and interpreted.
成本效益分析(CEA)可以为如何投资有限的资金提供有用的信息,但是如果对同一干预措施的不同分析提供了不清楚或矛盾的结果,那么它们的作用就不大了。我们的研究目的是对评估潜伏性结核感染(LTBI)的干扰素γ释放测定(IGRA)的成本效益分析的方法学方面进行系统评价,以了解差异如何影响研究结果。
对研究进行了系统评价,特别关注研究质量和用于评估成本效益的模型中使用的输入变量的可变性。开发了一个 IGRA 与结核菌素皮肤试验(TST)筛查策略的通用决策分析模型,并用于量化从确定的研究中观察到的模型输入差异对预测结果的影响。
最终有 13 项研究被纳入综述。在研究中发现了几个具体的方法学问题,包括如何选择研究输入、成本核算方法的不一致性、QALY(质量调整生命年)作为有效性结果的效用,以及作者如何选择和解释研究结果。当使用我们的通用决策分析模型比较 IGRA 与 TST 测试策略时,预测的有效性结果基本重叠。
在评估 IGRA 测试成本效益的研究中,发现了许多导致结果不一致和研究质量降低的方法学问题。需要更具体和相关的指南,以帮助作者规范建模方法、输入、假设以及结果的呈现和解释。